Increased activity of surviving locus ceruleus neurons in Alzheimer's disease

Annals of Neurology

Volumn 45, Issue 1, 1999, Pages 82-91

  Hoogendijk, Witte J G ^a,b   Feenstra, Matthijs G P ^a   Botterblom, Margriet H A ^a   Gilhuis, Job ^a   Sommer, Iris E C ^a   Kamphorst, Wouter ^a   Eikelenboom, Piet ^a   Swaab, Dick F ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b Valerius Clinic   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; DOPAMINE; HOMOVANILLIC ACID; NORADRENALIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DOPAMINERGIC SYSTEM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LOCUS CERULEUS; MALE; NERVE CELL STIMULATION; NORADRENERGIC SYSTEM; PRIORITY JOURNAL;

3,4-DIHYDROXYPHENYLACETIC ACID; ALZHEIMER DISEASE; AMYGDALA; CELL COUNT; CELL SURVIVAL; DOPAMINE; FEMALE; HIPPOCAMPUS; HOMOVANILLIC ACID; HUMANS; LOCUS COERULEUS; LONGITUDINAL STUDIES; MALE; NEURONS; NOREPINEPHRINE; SEROTONIN; SYMPATHOMIMETICS; TEMPORAL LOBE; THALAMUS;

EID: 0032924926     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199901)45:1<82::AID-ART14>3.0.CO;2-T     Document Type: Article

References (58)

1. Tomlinson BE, Irving D, Blessed G. Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci 1981;49:419-428
2. Hoogendijk WJG, Pool ChW, Troost D, et al. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain 1995;118:131-143
3. Gottfries CG. Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology 1985;86:245-252
4. Robbins TW, Everitt BJ. Central norepinephrine neurons and behavior. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:363-372
5. Zubenko GS, Moossy J, Kopp U. Neurochemical correlates of major depression in primary dementia. Arch Neurol 1990;47: 209-214
6. Zubenko GS, Moossy J. Major depression in primary dementia: clinical and neuropathological correlates. Arch Neurol 1988;45: 1182-1186
7. Zweig RM, Ross CA, Hedreen JC, et al. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann Neurol 1988; 24:233-242
8. Förstl H, Burns A, Luthert P, et al. Clinical and neuropathological correlates of depression in Alzheimer's disease. Psychol Med 1992;22:877-884
9. Scheinin H, MacDonald E, Scheinin M. Comparison of free MHPG in rat cerebrospinal fluid with free and conjugated MHPG in brain tissue: effects of drugs modifying noradrenergic transmission. Eur J Pharmacol 1986;129:113-121
10. Lookingland KJ, Ireland LM, Gunnet JW, et al. 3-Methoxy-4-hydroxyphenylethyleneglycol concentrations in discrete hypothalamic nuclei reflect the activity of noradrenergic neurons. Brain Res 1991;559:82-88
11. Gottfries CG, Adolfsson R, Aquilonius SM, et al. Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 1983;4:261-271
12. Palmer AM, Wilcock GK, Esiri MM, et al. Monoaminergic innervation of the frontal and temporal lobes in Alzheimer's disease. Brain Res 1987;401:231-238
13. Herregodts P, Bruyland M, De Keyser J, et al. Monoaminergic neurotransmitters in Alzheimer's disease. An HPLC study comparing presenile familial and sporadic senile cases. J Neurol Sci 1989;92:101-116
14. Bierer LM, Haroutunian V, Gabriel S, et al. Neurochemical correlates of dementia severity in Alzheimer's disease: relative importance of the cholinergic deficits. J Neurochem 1995;64: 749-760
15. Zigmond MJ, Stricker EM. Adaptive properties of monoaminergic neurons. In: Lajtha A, ed. Handbook of neurochemistry, vol 9: alterations of metabolites in the nervous system. New York: Plenum Press, 1985:87-102
16. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1986;45:19-34
17. Calne DB, Zigmond MJ. Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. Arch Neurol 1991;48:361-363
18. Abercrombie ED, Zigmond MJ. Partial injury to central noradrenergic neurons: reduction of tissue norepinephrine content is greater than reduction of extracellular norepinephrine measured by microdialysis. J Neurosci 1989;9:4062-4067
19. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944
20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association, 1987:97-123, 213-233
21. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the mental state of patients for the clinician. J Psychiatr Res 1975;12:189-198
22. Reisberg B, Ferris SH, de Leon MJ, Crook T. Global deterioration scale. Psychopharmacol Bull 1988;24:661-663
23. Reisberg B. Functional assessment staging. Psychopharmacol Bull 1988;24:653-659
24. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
25. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell scale for depression in dementia. Biol Psychiatry 1988;23: 271-284
26. National Institutes of Health Consensus Development Conference, November 4-6, 1991, Washington, DC
27. Alexopoulos GS. The treatment of depressed demented patients. J Clin Psychiatry 1996;57(Suppl 14):14-20
28. Zubenko GS. Clinicopathological and neurochemical correlates of depression and psychosis in primary dementia. Int Psychogeriatr 1996;8(Suppl 3):219-223
29. Braak H, Braak E, Yilmazer D, et al. Pattern of brain destruction in Parkinson's and Alzheimer's disease. J Neural Transm 1996;103:455-490
30. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-486
31. Westerink BH. Correlation between high-performance liquid chromatography and automated fluorimetric methods for the determination of dopamine, 3,4-dihydroxyphenylacetic acid, homovanillic acid and 5-hydroxyindoleacetic acid in nervous tissue and cerebrospinal fluid. J Chromatogr 1982;233:69-77
32. Feenstra MGP, Kalsbeek A, van Galen H. Neonatal lesions of the ventral tegmental area affect monoaminergic responses to stress in the medial prefrontal cortex and other dopamine projection areas in adulthood. Brain Res 1992;596:169-182
33. Smedes F, Kraak JC, Poppe H. Simple and fast solvent extraction system for selective and quantitative isolation of epinephrine, norepinephrine and dopamine from plasma and urine. J Chromatogr 1982;231:25-39
34. Palmer AM, Francis PT, Bowen DM, et al. Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease. Brain Res 1987;414:365-375
35. Hankoff LD, Perress NS. Neuropathology of the brain stem in psychiatric disorders. Biol Psychiatry 1981;16:945-952
36. Klimek V, Stockmeier C, Overholser J, et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 1997;17:8451-8458
37. Cheethem SC, Katona CLE, Horton RW. Post-mortem studies of neurotransmitter biochemistry in depression and suicide. In: Horton R, Katona C, eds. Biological aspects of affective disorders. London: Academic Press, 1991:192-221
38. Potter WZ, Manji HK. Catecholamines in depression: an update. Clin Chem 1994;40:279-287
39. Perry EK, Tomlinson BE, Blessed G, et al. Neuropathological and biochemical observations on the noradrenergic system in Alzheimer's disease. J Neurol Sci 1981;51:279-287
40. Burke WJ, Rubin EH, Morris JC, Berg L. Symptoms of "depression" in dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1988;2:356-362
41. Zweig RM, Cardillo JE, Cohen M, et al. The locus coeruleus and dementia in Parkinson's disease. Neurology 1993;43:986-991
42. Mann DM, Yates PO, Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J Neurol Neurosurg Psychiatry 1982;45:113-119
43. Palmer AM, DeKosky ST. Monoamine neurons in aging and Alzheimer's disease. J Neural Transm Gen Sect 1993;91:135-159
44. Palmer AM. The stability of 5-hydroxyindoleacetic acid and noradrenaline in normal and Alzheimer postmortem brain. Biochem Soc Trans 1986;14:608-609
45. Ravid R, Van Zwieten EJ, Swaab DF. Brain banking and the human hypothalamus - factors to match for, pitfalls and potentials. Prog Brain Res 1992;93:83-95 (Review)
46. MacKay AV, Yates CM, Wright A, et al. Regional distribution of monoamines and their metabolites in the human brain. J Neurochem 1978;30:841-848
47. Palmer AM. The stability of 5-hydroxyindoleacetic acid and norepinephrine in normal and Alzheimer post mortem brain. Biochem Soc Trans 1986;14:608-609
48. Adolfsson R, Gottfries CG, Roos BE, Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry 1979;135:216-223
49. Arai H, Kosaka K, lizuka R. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 1984;43:388-393
50. Nazarali AJ, Reynolds GP. Monoamine neurotransmitters and their metabolites in brain regions in Alzheimer's disease: a post-mortem study. Cell Mol Neurobiol 1992;12:581-587
51. Storga D, Vrecko K, Birkmayer JG, Reibnegger G. Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neurosci Lett 1996;203:29-32
52. Gsell W, Strein I, Riederer P. The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. J Neural Transm Suppl 1996;47:73-101
53. Ichimiya Y, Arai H, Kosaka K, lizuka R. Morphological and biochemical changes in the cholinergic and monoaminergic systems in Alzheimer-type dementia. Acta Neuropathol (Berl) 1986;70:112-116
54. Bondareff W, Mountjoy CQ, Roth M, et al. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis Assoc Disord 1987;1:256-262
55. Hallman H, Jonsson G. Pharmacological modifications of the neurotoxic action of the norepinephrine neurotoxin DSP4 on central norepinephrine neurons. Eur J Pharmacol 1984;103: 269-278
56. Logue MP, Growdon JH, Coviella ILG, Wurtman RJ. Differential effects of DSP-4 administration on regional brain norepinephrine turnover in rats. Life Sci 1985;37:403-409
57. Zigmond MJ, Acheson AL, Stachowiak MK, Stricker EM. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch Neurol 1984;41:856-861
58. Schwab RS, Zeiper I. Effects of mood, motivation, stress and alertness on the performance in Parkinson's disease. Psychiatr Neurol (Basel) 1965;150:345-357